The numbers from 2025 tell a story that would have seemed implausible a decade ago: license-out deals involving China-based biotechs reached a record $137.7 billion in total announced value, up nearly tenfold from 2021 levels, according to data provider PharmCube. In 2026, the momentum has not only continued — it has intensified. Average deal sizes have jumped 76%, upfront fees have doubled, and the therapeutic breadth of deals has expanded well beyond the ADC and bispecific antibody plays that defined earlier waves of China-focused dealmaking.
The shift is structural, not cyclical. Western pharma has fundamentally repositioned its sourcing strategy, treating China’s expanding pipeline not as a repository of cheap me-too drugs, but as an essential infrastructure layer for next-generation therapeutics.
Why China, Why Now
Several dynamics converged to produce this inflection. First, China’s biopharma ecosystem has matured dramatically. Over the past decade, the country has built out a deep talent base, state-supported research infrastructure, and a regulatory environment that has accelerated the pace of early-stage drug development. China’s NMPA (National Medical Products Administration) has progressively aligned its standards with ICH guidelines, making regulatory data from Chinese trials more acceptable to Western regulators.
Second, the economics of drug development have pushed Western pharma toward earlier engagement with China-based assets. As R&D costs have risen and pipeline productivity has declined, acquiring or licensing validated early-stage candidates from Chinese biotechs has become a cost-effective strategy — particularly for targets like ADCs, bispecifics, and GLP-1 receptor agonists where Chinese companies have built meaningful leads.
Third, the patent cliff facing several Western blockbuster drugs has intensified the search for differentiated assets. Rather than competing directly on crowded mechanisms, large pharma has found in China’s biotech ecosystem a source of genuinely novel chemistry and biology.
Deal Highlights: From ADCs to GLP-1
The 2025–2026 wave of licensing deals spans a remarkable range of therapeutic modalities and targets.
AstraZeneca and CSPC Pharmaceutical Group signed a deal worth up to $18.5 billion for GLP-1 receptor agonist assets — a transaction that signaled to the entire industry that China’s obesity and metabolic disease pipeline had reached global competitive standing.
AbbVie secured rights to RemeGen’s disitamab vedotin, an ADC targeting HER2, in a deal valued at up to $5.6 billion — confirming the sustained appetite for ADC platforms even after a wave of prior acquisitions.
Pfizer partnered with 3SBio in a transaction worth up to $6.05 billion for an ADC asset, while Madrigal Pharmaceuticals licensed Ribo Lifesciences’ thyroid hormone receptor-beta agonist for $4.4 billion, reflecting the high valuations commanded by NASH/MASH candidates.
In the bispecific antibody space, Bristol Myers Squibb’s partnership with Harbour BioMed — valued at up to $1.1 billion — gave the U.S. pharma access to Harbour’s proprietary bispecific platform and a pipeline of bispecific candidates.
The Geopolitical Resilience Factor
What makes the China licensing surge particularly remarkable is its resilience against a deteriorating geopolitical backdrop. Despite continued U.S.-China tensions and increasing scrutiny of cross-border biotech deals by both CFIUS and Chinese regulators, deal flow has not merely persisted — it has accelerated.
The reason is straightforward: the science is too good to ignore. When a pipeline asset offers genuine differentiation on a validated but difficult target, commercial logic tends to override political risk calculations — particularly when the alternative is facing that same competitor through a different channel.
Western companies have also become more sophisticated about deal structuring, using creative structures — upfront payments, milestone-linked tranches, and co-development arrangements — that allow them to participate in upside while managing headline exposure.
2026 Outlook: Broadening and Deepening
The licensing boom shows every sign of sustaining through 2026 and beyond. Jefferies estimates that one-third of the industry’s total licensing spending in 2025 involved drugs sourced from China — a proportion that is likely to increase as more Chinese-developed candidates enter the global clinic.
Pitchbook notes that China’s advantage in early-stage drugmaking is “likely to persist,” citing the country’s concentrated expertise in specific modalities — particularly ADCs, bispecifics, and cell therapies — as well as a manufacturing ecosystem that continues to drive down costs for biologics production.
For Western companies, the strategic question is no longer whether to engage with China’s biotech ecosystem, but how to structure those relationships most effectively. For investors and analysts, the $137.7 billion figure from 2025 is less a ceiling than a floor.
原文：https://www.biopharmadive.com/news/china-biotech-drug-licensing-deals-pipeline/758283/
Published at: May 4, 2026 · Modified at: May 4, 2026
